News Releases

– Third-quarter results reflect revenue of $183.5 million driven by the FDA approval of SimpleScreen™ CRC – – Entered the public market and raised gross proceeds of $310 million – BRISBANE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (NASDAQ: FRNM), a personalized cancer detection
November 10, 2026